Combining NVP-BEZ235 and Sorafenib for Renal Cell Carcinoma Treatment
Author Information
Author(s): Roulin Didier, Waselle Laurent, Dormond-Meuwly Anne, Dufour Marc, Demartines Nicolas, Dormond Olivier
Primary Institution: Centre Hospitalier Universitaire Vaudois and University of Lausanne
Hypothesis
Does the combination of NVP-BEZ235 and sorafenib enhance the treatment efficacy for renal cell carcinoma compared to each drug alone?
Conclusion
The combination of NVP-BEZ235 and sorafenib provides greater antitumor benefits than either drug alone in renal cell carcinoma.
Supporting Evidence
- NVP-BEZ235 and sorafenib reduced tumor cell proliferation and increased apoptosis in vitro.
- The combination treatment was more effective than either drug alone.
- In vivo, the combination treatment significantly reduced tumor growth compared to monotherapy.
- The study suggests a new treatment strategy for advanced renal cell carcinoma.
Takeaway
Using two medicines together can help fight kidney cancer better than using just one medicine by making the cancer cells die faster.
Methodology
The study involved treating renal carcinoma cell lines with NVP-BEZ235 and sorafenib, both alone and in combination, and evaluating their effects on cell proliferation and apoptosis in vitro, as well as on tumor growth in vivo using xenograft models.
Potential Biases
Potential bias in the selection of cell lines and animal models used for the study.
Limitations
The study primarily focused on two cell lines and may not represent all types of renal cell carcinoma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website